Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT05553093

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05553093
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05553093. Randomized; no masking; primary purpose treatment. Start 2022-03-15 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Insulin Glargine
Lead sponsor
Nanjing First Hospital, Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct05553093
Content hash
2a80b5f1418000645eeb9f835187a6131c6585faf10130612962566c5c623b0c